Physician profile
James Egan
NPI 1346357696
$1,265.91
in general payments reported to CMS, 2019-2025
17 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $19.39 · 2021: $103 · 2022: $49.96 · 2023: $217 · 2024: $139 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.59 | 2019-2025 | Viberzi, Linzess |
| Pfizer INC. | $231.49 | 2019-2025 | |
| Genzyme Corporation | $160.05 | 2023-2024 | |
| Janssen Biotech, INC. | $63.14 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $45.20 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $44.62 | 2025 | Rezdiffra |
| Allergan, INC. | $43.43 | 2019 | |
| Boston Scientific Corporation | $42.74 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $39.33 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $36.80 | 2019-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $31.93 | 2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $21.87 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $21.73 | 2023 | Entyvio |
| Phathom Pharmaceuticals, INC. | $21.02 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.88 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.50 | 2019 | |
| Celgene Corporation | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.